Understanding Spinal Muscular Atrophy: Types, Causes, and Management
Updated: 3 days ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026
Quick Answer: What Is Spinal Muscular Atrophy?
Spinal muscular atrophy is an inherited condition in which loss of motor neurons in the spinal cord causes muscle wasting and weakness, mostly in muscles closest to the body's center, like the neck and legs. It is caused by SMN1 gene mutations. Genetic testing confirms it, and care includes disease-modifying treatment, therapy and respiratory support. [1]
What the research says
SMA is rare, and type 1 is the most common form. A literature review estimated an incidence of around 1 in 10,000 live births and a prevalence of about 1 to 2 per 100,000 people, with type 1 accounting for roughly 60% of cases. Carrier frequency appears higher in Caucasian and Asian populations than in Black populations, and the authors note that most older studies relied on clinical rather than genetic diagnosis (Verhaart et al., Orphanet Journal of Rare Diseases, 2017).
Early treatment improved survival and movement in infants. In the industry-funded ENDEAR trial of nusinersen versus a sham procedure, 51% of treated infants (37 of 73) met a motor-milestone response versus 0% of controls (0 of 37). The hazard ratio for death or permanent assisted ventilation was 0.53, and for death it was 0.37. Infants with a shorter disease duration benefited more (Finkel et al., New England Journal of Medicine, 2017).
What Is Spinal Muscular Atrophy?
SMA is a group of inherited neuromuscular disorders in which certain muscles become weak and waste away, a process called atrophy [1]. It involves the loss of lower motor neurons, the nerve cells in the spinal cord that control muscle movement. Without them, muscles do not receive the nerve signals they need to work, and they deteriorate over time. The weakness is typically more severe in proximal muscles, which are close to the center of the body, than in distal muscles farther away.
What Are the Five Subtypes of SMA?
Healthcare professionals classify SMA into five subtypes based on the age when symptoms first appear, the severity, and the typical outlook. They range from type 0, which affects a fetus before birth, to type 4, which appears in adulthood [1].
Subtype | Typical age of onset | Severity and mobility | Typical course without disease-modifying treatment |
|---|---|---|---|
Type 0 | Before birth (prenatal) | Severe weakness; breathing failure | Usually from birth to one month |
Type 1 | Under 6 months | Limited head control; cannot sit | Often under two years without support |
Type 2 | 6 to 18 months | Can sit but usually cannot walk | Often survives to 25–30 years or beyond |
Type 3 | After 18 months | Difficulty walking; slow progression | Typically a normal life expectancy |
Type 4 | Adulthood (often after age 21) | Mild leg weakness; remains mobile | Normal life expectancy |
The last column describes the typical natural course without disease-modifying treatment. In a clinical trial, treatment started early improved survival and motor function in infants [3], so outlook depends on the subtype, when treatment starts, and the care a person receives.
What Are the Symptoms of SMA?
The main symptom of every SMA type is muscle weakness, but how it looks varies by subtype. Infants with type 1 often have limited head control and no reflexes, along with a bell-shaped chest and abnormal breathing. Trouble swallowing can lead to growth problems. Children with type 2 may develop scoliosis, restrictive lung disease, and joint contractures, along with jerky hand movements [1].
Type 0: Decreased fetal movement, severe muscle weakness, and breathing problems right after birth.
Type 1: Hypotonia (low muscle tone), absent reflexes (areflexia), and inability to sit without support.
Type 2: Progressive weakness that affects the legs more than the arms, scoliosis, and jaw stiffening.
Type 3: Progressive leg weakness that leads to mobility challenges later in childhood.
Type 4: Mild leg weakness that progresses slowly through adulthood.
What Causes SMA, and How Is It Inherited?
SMA is caused by mutations in the SMN1 (survivor motor neuron 1) gene [1]. This gene makes the SMN protein, which motor neurons need to survive and work. When the body does not make enough of it, motor neurons shrink and die, and the brain can no longer control voluntary movement.
Genetic factor | Role in SMA | Effect on severity |
|---|---|---|
SMN1 gene | The main source of SMN protein. | Mutations in this gene cause SMA. |
SMN2 gene | Makes a small amount of SMN protein. | Extra copies (up to 8) can lessen symptoms. |
SMA follows an autosomal recessive pattern: a person must inherit a mutated SMN1 gene from both biological parents to develop it. Carriers, who have only one mutated copy, typically have no symptoms. Carrier frequency varies by ancestry and appears higher in Caucasian and Asian populations [2].
How Is SMA Diagnosed?
Genetic testing is the main way to diagnose SMA. A blood test looks for changes in the SMN1 gene and confirms most cases [1]. In the United States, SMA is now part of routine newborn screening. If symptoms are present but SMA is not immediately suspected, other tests may be used to rule out similar neuromuscular conditions.
Genetic testing: A blood test to identify SMN1 gene mutations.
Creatine kinase test: Checks for muscle breakdown (typically normal in SMA).
EMG and nerve conduction studies: Measure the electrical activity of nerves and muscles.
Muscle biopsy: Rarely needed; examines muscle tissue in a lab.
Prenatal testing: Amniocentesis or chorionic villus sampling for families with a history of the condition.
How Is SMA Managed?
There is currently no cure for SMA, but treatment can change its course and care focuses on easing symptoms, preventing complications, and improving daily function [1]. A team of specialists usually works together.
Disease-modifying medicines: Newer treatments may work best when started early, even before symptoms appear [1]. In the ENDEAR trial, nusinersen, given by injection around the spinal cord, improved survival and motor milestones in infants [3].
Physical and occupational therapy: Help maintain mobility and joint flexibility.
Respiratory support: Critical for people with more severe subtypes who have breathing difficulties.
Nutritional support: May be needed when swallowing is difficult.
Spine care: Scoliosis is common and may need bracing or other treatment.
Conclusion
Spinal muscular atrophy is a complex genetic disorder that affects muscle function and mobility. Its subtypes vary widely, so each person's experience differs. Early diagnosis through newborn screening, early treatment, and proactive supportive care are essential for addressing the physical and breathing challenges of the condition.
When should you talk to a healthcare professional about spinal muscular atrophy?
If you have a family history of neuromuscular disorders, or you notice signs of progressive muscle weakness in yourself or your child, talk to a healthcare professional about genetic counseling and evaluation. Early intervention and a specialized care plan matter for managing SMA.
Frequently Asked Questions
Is spinal muscular atrophy contagious?
No. SMA is a genetic condition inherited from biological parents. It cannot be spread through contact.
Can adults develop SMA?
Yes. SMA type 4 is the adult-onset form. It appears in adulthood with mild symptoms, usually mild leg weakness that progresses slowly.
How common is SMA?
A literature review estimated an incidence of around 1 in 10,000 live births and a prevalence of about 1 to 2 per 100,000 people, with type 1 making up roughly 60% of cases [2].
What is the difference between proximal and distal muscles?
Proximal muscles are closer to the center of the body (such as the neck and hips), while distal muscles are farther away (such as the hands and feet). SMA weakness is typically more severe in proximal muscles [1].
Can SMA be prevented?
As a genetic condition, SMA cannot be prevented, but genetic counseling can help families understand their risk.
What is hypotonia?
Hypotonia means decreased muscle tone. It often makes an infant seem floppy and limits motor control.
Does SMA affect intelligence?
No. SMA affects motor neurons, which control movement, and it is not known to impair thinking or intelligence.
What is Werdnig-Hoffmann disease?
Werdnig-Hoffmann disease is another name for SMA type 1, the severe form that appears in early infancy.
Why is the SMN2 gene important?
The SMN2 gene makes a small amount of SMN protein. Having more copies of SMN2 can lessen symptoms.
Can infants with SMA type 1 sit up?
Typically no. Infants with type 1 SMA cannot sit without significant support because of severe muscle weakness.
What causes death in severe SMA?
Respiratory failure and complications of restrictive lung disease are the most common causes in the severe types.
Is a muscle biopsy always necessary for diagnosis?
No. A muscle biopsy is rarely needed, because genetic testing can confirm most cases of SMA.
What is scoliosis in SMA?
Scoliosis is a curve of the spine. It often develops in children with SMA because the muscles that support the back are weak.
Are all newborns screened for SMA?
SMA is now included in routine newborn screening in the United States. Early diagnosis matters because treatment may work best when it starts early [3].
Can people with SMA type 3 walk?
Many people with type 3 SMA can walk, although they may find it increasingly difficult as they get older.
Related Reading
Prenatal Genetic Testing: Screening vs Diagnostic Tests, Timing and Accuracy explains the screening and diagnostic tests that can detect this condition during pregnancy.
References
Cleveland Clinic. Spinal muscular atrophy (SMA). Cleveland Clinic Health Library. Source content dated June 6, 2024. https://my.clevelandclinic.org/health/diseases/14505-spinal-muscular-atrophy-sma
Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy: a literature review. Orphanet Journal of Rare Diseases. 2017;12(1):124. PMID 28676062. https://doi.org/10.1186/s13023-017-0671-8
Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. The New England Journal of Medicine. 2017;377(18):1723-1732. PMID 29091570. https://doi.org/10.1056/NEJMoa1702752
Medical disclaimer
This guide is based on medical information dated June 6, 2024. Always consult a healthcare professional for diagnosis and treatment decisions.
Health information, not medical advice. This article is for general education and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your own health, and seek emergency care for urgent symptoms.
Comments